@annovisbio Avatar @annovisbio Annovis Bio

Annovis Bio posts on YouTube about ceo, in the, $anvs, drugs the most. They currently have [---] followers and [--] posts still getting attention that total [---] engagements in the last [--] hours.

Engagements: [---] #

Engagements Line Chart

Mentions: [--] #

Mentions Line Chart

Followers: [---] #

Followers Line Chart

CreatorRank: undefined #

CreatorRank Line Chart

Social Influence

Social category influence stocks finance

Social topic influence ceo, in the, $anvs #7, drugs, update, data, virtual, money, interview, vision

Top assets mentioned Annovis Bio Inc. (ANVS)

Top Social Posts

Top posts by engagements in the last [--] hours

"Annovis Bio's Breakthroughs in Alzheimer's and Parkinson's: Full Pitch and Q&A on Virtual Investor Full episode of "The Pitch" on Virtual Investor featuring Dr. Maria Maccecchini Founder President and CEO of Annovis Bio. In this insightful session Dr. Maccecchini delivers a compelling five to seven-minute pitch followed by an engaging and detailed Q&A session that has garnered positive feedback from viewers. In this episode Dr. Maccecchini discusses Annovis Bio's groundbreaking work in developing novel therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. She"
YouTube Link 2024-06-19T16:54Z [---] followers, [---] engagements

"H.C. Wainwright [----] - ANVS Presentation September 10"
YouTube Link 2025-09-15T15:55Z [---] followers, [---] engagements

"Annovis (ANVS) featured on Money Matters 6/14/24 In this Money Matters TV interview host Dan chats with Maria Maccecchini the CEO and founder of Annovis Bio. Established in [----] Annovis Bio focuses on developing innovative therapeutics for neurodegenerative diseases like Alzheimer's and Parkinson's. Maria shares her extensive experience in the pharmaceutical industry detailing the company's journey and the promising developments of their drugs. She discusses the challenges in drug development the significant progress made and the plans for future studies. This insightful conversation"
YouTube Link 2024-06-14T16:51Z [---] followers, [---] engagements

"Annovis Year-End Investor Webcast on December [--] [----] Join us for the Annovis Bio Year-End Investor Webcast where Dr. Maria Maccecchini Founder President and CEO of Annovis Bio provides a comprehensive update on the companys [----] achievements ongoing clinical programs and strategic initiatives for [----]. This webcast includes highlights on: Progress in pivotal Phase [--] Alzheimers and Parkinsons disease studies. Financial updates and fundraising strategies. The latest clinical trial developments for buntanetap. Insights into the companys vision for the future of neurodegenerative disease"
YouTube Link 2024-12-12T02:43Z [---] followers, [----] engagements

"Annovis Bio Web Cast 6/11/2024 Maria Maccecchini PhD CEO of Annovis Bio In this video Dr. Maria Maccecchini CEO of Annovis Bio discusses the latest Alzheimers data from the Phase II/III study of their lead drug candidate Buntanetap. She also provides an update on the drugs safety and efficacy particularly in carriers of APOE4 a genetic cause for Alzheimers. Key highlights include: Buntanetap demonstrated efficacy in improving cognition in early Alzheimers patients positioning it as a promising symptomatic treatment with a stronger cognitive response compared to currently approved therapies."
YouTube Link 2024-06-12T12:10Z [---] followers, [---] engagements

"Annovis Webinar January [--] 2026"
YouTube Link 2026-01-29T03:54Z [---] followers, [---] engagements

"Annovis Patients' Live Forum: Your Questions Answered (February [--] 2025) In this webcast Dr. Maccecchini CEO of Annovis Bio provides updates on the ongoing Phase [--] Alzheimer's trial plans for the Phase [--] Parkinson's and Open Label Extension studies and answers questions from the live audience. For more information about Annovis Bio visit: www.annovisbio.com. Subscribe for updates and follow us for more announcements"
YouTube Link 2025-02-28T02:03Z [---] followers, [---] engagements

"Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace Join Annovis Founder President and CEO Maria Maccecchini PhD and Dr. Scott Shipman MD MPH as they discuss groundbreaking advancements in the treatment of neurodegenerative diseases on Todays Marketplace. Learn about Annovis innovative once-a-day pill which not only slows the progression of Alzheimers and Parkinsons diseases but also improves symptoms such as cognition and function. Discover how these breakthroughs are transforming care by enhancing patients' lives empowering caregivers and"
YouTube Link 2024-12-03T13:30Z [---] followers, 11K engagements

"Annovis Webinar and Live Q&A - June [--] [----] Annovis' CEO Maria Maccecchini Ph.D. provides updates on the Company's ongoing pivotal Phase [--] clinical trial in early Alzheimer's next steps for Parkinson's program and answers live questions from the audience"
YouTube Link 2025-06-24T22:11Z [---] followers, [---] engagements

"Annovis Bio Presents Promising Phase III Parkinsons Data Annovis Bio Announces New Data from Phase III Parkinsons Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinsons patients with substantial cognitive decline exhibited a very pronounced improvement. Buntanetap showed statistical improvement in the MDS-UPDRS Part II Part III Part II+III and Total scores in Parkinsons patients"
YouTube Link 2024-07-02T23:44Z [---] followers, [----] engagements

"Annovis Webinar January [--] 2026"
YouTube Link 2026-01-29T03:54Z [---] followers, [---] engagements

"H.C. Wainwright [----] - ANVS Presentation September 10"
YouTube Link 2025-09-15T15:55Z [---] followers, [---] engagements

"Annovis Webinar and Live Q&A - June [--] [----] Annovis' CEO Maria Maccecchini Ph.D. provides updates on the Company's ongoing pivotal Phase [--] clinical trial in early Alzheimer's next steps for Parkinson's program and answers live questions from the audience"
YouTube Link 2025-06-24T22:11Z [---] followers, [---] engagements

"Annovis Patients' Live Forum: Your Questions Answered (February [--] 2025) In this webcast Dr. Maccecchini CEO of Annovis Bio provides updates on the ongoing Phase [--] Alzheimer's trial plans for the Phase [--] Parkinson's and Open Label Extension studies and answers questions from the live audience. For more information about Annovis Bio visit: www.annovisbio.com. Subscribe for updates and follow us for more announcements"
YouTube Link 2025-02-28T02:03Z [---] followers, [---] engagements

"Annovis Year-End Investor Webcast on December [--] [----] Join us for the Annovis Bio Year-End Investor Webcast where Dr. Maria Maccecchini Founder President and CEO of Annovis Bio provides a comprehensive update on the companys [----] achievements ongoing clinical programs and strategic initiatives for [----]. This webcast includes highlights on: Progress in pivotal Phase [--] Alzheimers and Parkinsons disease studies. Financial updates and fundraising strategies. The latest clinical trial developments for buntanetap. Insights into the companys vision for the future of neurodegenerative disease"
YouTube Link 2024-12-12T02:43Z [---] followers, [----] engagements

"Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace Join Annovis Founder President and CEO Maria Maccecchini PhD and Dr. Scott Shipman MD MPH as they discuss groundbreaking advancements in the treatment of neurodegenerative diseases on Todays Marketplace. Learn about Annovis innovative once-a-day pill which not only slows the progression of Alzheimers and Parkinsons diseases but also improves symptoms such as cognition and function. Discover how these breakthroughs are transforming care by enhancing patients' lives empowering caregivers and"
YouTube Link 2024-12-03T13:30Z [---] followers, 11K engagements

"Annovis Bio Presents Promising Phase III Parkinsons Data Annovis Bio Announces New Data from Phase III Parkinsons Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinsons patients with substantial cognitive decline exhibited a very pronounced improvement. Buntanetap showed statistical improvement in the MDS-UPDRS Part II Part III Part II+III and Total scores in Parkinsons patients"
YouTube Link 2024-07-02T23:44Z [---] followers, [----] engagements

"Annovis Bio's Breakthroughs in Alzheimer's and Parkinson's: Full Pitch and Q&A on Virtual Investor Full episode of "The Pitch" on Virtual Investor featuring Dr. Maria Maccecchini Founder President and CEO of Annovis Bio. In this insightful session Dr. Maccecchini delivers a compelling five to seven-minute pitch followed by an engaging and detailed Q&A session that has garnered positive feedback from viewers. In this episode Dr. Maccecchini discusses Annovis Bio's groundbreaking work in developing novel therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. She"
YouTube Link 2024-06-19T16:54Z [---] followers, [---] engagements

"Annovis (ANVS) featured on Money Matters 6/14/24 In this Money Matters TV interview host Dan chats with Maria Maccecchini the CEO and founder of Annovis Bio. Established in [----] Annovis Bio focuses on developing innovative therapeutics for neurodegenerative diseases like Alzheimer's and Parkinson's. Maria shares her extensive experience in the pharmaceutical industry detailing the company's journey and the promising developments of their drugs. She discusses the challenges in drug development the significant progress made and the plans for future studies. This insightful conversation"
YouTube Link 2024-06-14T16:51Z [---] followers, [---] engagements

"Annovis Bio Web Cast 6/11/2024 Maria Maccecchini PhD CEO of Annovis Bio In this video Dr. Maria Maccecchini CEO of Annovis Bio discusses the latest Alzheimers data from the Phase II/III study of their lead drug candidate Buntanetap. She also provides an update on the drugs safety and efficacy particularly in carriers of APOE4 a genetic cause for Alzheimers. Key highlights include: Buntanetap demonstrated efficacy in improving cognition in early Alzheimers patients positioning it as a promising symptomatic treatment with a stronger cognitive response compared to currently approved therapies."
YouTube Link 2024-06-12T12:10Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing